-
The market structure will change! 8 varieties of 9 pharmaceutical companies including Zhengda Tianqing, Hausen, Jialin, and Huahai were approved and passed the consistency evaluation
Time of Update: 2018-05-23
This is the fourth batch of products that have passed the conformity assessment since the implementation of the quality and efficacy conformity assessment policy for generic drugs So far, a total of 2
-
New 1 billion varieties of Kelun pharmaceutical will be born! Is it courage or strength to challenge Roche?
Time of Update: 2018-05-23
Recently, Kelun pharmaceutical announced that the antibody coupling drug "a166 for injection" developed by the subsidiary Sichuan Kelun Botai Biological Technology Co., Ltd was approved by CFDA after
-
Another big wave of varieties apply for protection of traditional Chinese medicine! Tianshili, Kangyuan, Zhengda Tianqing and Cr double review crane are listed
Time of Update: 2018-05-21
On May 16, the National Committee for the protection and review of traditional Chinese medicine varieties issued several lists of traditional Chinese medicine protection data receiving varieties and s
-
Novartis, Roche, Pfizer Who has applied for the most clinical trials of top 10 pharmaceutical companies in China? Who withdraws the most?
Time of Update: 2018-05-21
For medical people, "5.20" should have a different color Who applies for the most clinical trials in China? Who completes the most? Who withdraws the most? Why? The answers are all in this article How
-
A-le is the first to pass the consistency evaluation, and the 10 billion market will be shuffled. Who is the next breakthrough?
Time of Update: 2018-05-20
Wonderful content on May 15, Dezhan health released a notice that its subsidiary, Beijing Jialin Pharmaceutical Co., Ltd., recently received the approval document for supplementary application of ator
-
Here comes the blockbuster! Zhengda Tianqing's 16 billion plus products are not enough, and new lung cancer drugs "explode" the market by 100 billion
Time of Update: 2018-05-18
Wonderful content recently, China biopharmaceutical announced that its subsidiary, androtinib hydrochloride capsule (trade name: fukewei), an anti-tumor class 1 Chemical independently developed by Tia
-
In recent years, the registration of "China's first class new drugs"
Time of Update: 2018-05-17
Since the national drug audit reform was launched in 2015, the design of relevant reform systems and the intensive release of supporting policies have opened the door for innovation in China's pharmac
-
18 pharmaceutical stocks including Hengrui and Fosun were included in the world's most influential stock index! How did you do it?
Time of Update: 2018-05-16
On May 15, MSCI, the world's most influential stock index, announced the final results of its semi-annual index adjustment, and officially accepted China's a shares into the MSCI Emerging Market Index
-
Domestic anti-cancer drugs add a new army! Zhengda Tianqing androtinib was approved. Who is the strong target drug market for lung cancer?
Time of Update: 2018-05-15
Recently, the National Drug Administration approved the launch of small molecule and multi-target receptor tyrosine kinase inhibitor androtinib hydrochloride capsule (focovide) for the treatment of ad
-
An analysis of recent developments in the field of orphan drug research and development in my country
Time of Update: 2018-05-14
Drugs, vaccines, diagnostic reagents, etc used to treat, diagnose and prevent rare diseases or rare states are called rare drugs or orphan drugs The incidence rate of rare diseases and common diseases
-
Hengrui's market value is over 250 billion yuan for the first time. Is it really just research and development? How to make marketing reform!
Time of Update: 2018-05-11
As of the closing on May 10, Hengrui pharmaceutical successfully topped the market value of 259.442 billion yuan with a price of 91.42 yuan / share, breaking the 250 billion yuan mark This is Hengrui pharmaceutical's new record of market value, and it is also the market value height that domestic pharmaceutical enterprises have never reached so far!
-
How long will it take for high-quality generic drugs to survive the consistency evaluation of variety recruitment and procurement?
Time of Update: 2018-05-10
In some places, the incentive policies of generic drug consistency evaluation have not been implemented, and generic drugs through the consistency evaluation have been repeatedly frustrated in bidding
-
Western bid price linkage! Pass the consistency evaluation and meet the price test again
Time of Update: 2018-05-09
On May 8, Qinghai provincial drug and medical consumables centralized purchase network released the announcement on carrying out online purchase of some drugs in public hospitals in Qinghai Province
-
Inventory: summary of listed "TiNi" drug information
Time of Update: 2018-05-08
As for Tinian drugs, some people said a few years ago that "it's almost over" and "it's broken", and many people are extremely dissatisfied with its research and development, that is, the so-called "w
-
166 Class I new drugs have been approved. Which products are the most representative in the 40 years of reform and opening up? Chinese pharmaceutical companies are marching into the world?
Time of Update: 2018-05-08
For China's pharmaceutical industry, the fortieth anniversary of reform and opening up is actually the forty years of industrial development At this stage, China's pharmaceutical industry has develope
-
18.5 billion sedation sleep market top 10 varieties momentum!
Time of Update: 2018-05-04
Sleep is an important part of improving human immune function Good sleep habits are very important When we can't get enough sleep under the influence of various pathological and psychological factors,
-
The domestic market of antiasthmatic inhalers has broken the 10 billion mark, and top 5 varieties account for more than 85%!
Time of Update: 2018-05-03
May 1 this year is the 20th World Asthma Day The World Health Organization launched this commemorative activity to strengthen the understanding of the current situation of asthma, attach importance to
-
The total market of antidepressants is over 10 billion yuan! Top 5 continuous development
Time of Update: 2018-04-20
Among the first batch of 12 products released on December 29, 2017 through the consistency evaluation of quality and efficacy of generic drugs, the selective 5-hydroxytryptamine reuptake inhibitor par
-
New trend: selection of non 289 varieties for consistency evaluation, enabling more than 1 billion large varieties of traditional Chinese Medicine
Time of Update: 2018-04-18
At the stage of time race, the time limit of related varieties is less than 300 days On April 13, the official website of the State Drug Administration released the catalogue of generic drugs approved
-
The list of domestic anti hemophilia drug "coagulation factor" is listed, only 2 domestic and 3 imported
Time of Update: 2018-04-18
Hemophilia is a group of haemorrhagic diseases caused by the deficiency of hereditary coagulation factors, mainly divided into type A and type B Among them, hemophilia A A is caused by the lack of coa
